dexefaroxan has been researched along with bromodeoxyuridine in 1 studies
| Studies (dexefaroxan) | Trials (dexefaroxan) | Recent Studies (post-2010) (dexefaroxan) | Studies (bromodeoxyuridine) | Trials (bromodeoxyuridine) | Recent Studies (post-2010) (bromodeoxyuridine) |
|---|---|---|---|---|---|
| 15 | 0 | 4 | 13,164 | 71 | 1,816 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colpaert, F; Debeir, T; Marien, M; Raisman-Vozari, R; Rizk, P; Ruberg, M; Salazar, J | 1 |
1 other study(ies) available for dexefaroxan and bromodeoxyuridine
| Article | Year |
|---|---|
The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Benzopyrans; Brain-Derived Neurotrophic Factor; Bromodeoxyuridine; Cell Count; Cell Differentiation; Cell Survival; Chromatography, High Pressure Liquid; Hippocampus; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Male; Microdialysis; Neural Cell Adhesion Molecule L1; Neurons; Norepinephrine; Rats; Rats, Sprague-Dawley; Sialic Acids; Time Factors | 2006 |